Article in ACS chemical neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
5 authors.
Xia LeiDepartment of Pharmacology and Warren Center for Neuroscience Drug Discovery, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.
Zixiu XiangDepartment of Pharmacology and Warren Center for Neuroscience Drug Discovery, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.ORCID 0000-0002-1678-209X
Alice L RodriguezDepartment of Pharmacology and Warren Center for Neuroscience Drug Discovery, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.ORCID 0000-0002-5244-5103
Margaret L WilsonDepartment of Pharmacology and Warren Center for Neuroscience Drug Discovery, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.
Colleen M NiswenderDepartment of Pharmacology and Warren Center for Neuroscience Drug Discovery, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.ORCID 0000-0001-6009-8212
Funding
Overall: Eunice Kennedy Shriver Intellectual and Developmental Disabilities Research Center at VanderbiltP50HD103537 · NICHD · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Jeffrey L Neul · 2020 to 2026
$10.3M
FUNCTIONS OF METABOTROPIC GLUTAMATE RECEPTOR SUBTYPESR01NS031373 · NINDS · VANDERBILT UNIVERSITY · PI CONN, P JEFFREY · 1993 to 2025
$6.2M
Development of mGlu7 receptor allosteric modulators for neurological and psychiatric disordersR01MH124671 · NIMH · VANDERBILT UNIVERSITY · PI LINDSLEY, CRAIG, NISWENDER, COLLEEN M · 2020 to 2024
$3.5M
Impact of Metabotropic Glutamate Receptor Heteromerization on Signaling and PharmacologyR01NS132060 · NINDS · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI Jonathan A Javitch, COLLEEN M NISWENDER · 2023 to 2026
$2.4M
Regulation of metabotropic glutamate receptor activity by protein/protein interactionsR01MH136164 · NIMH · VANDERBILT UNIVERSITY · PI COLLEEN M NISWENDER · 2025 to 2026
The group III metabotropic glutamate receptors (mGlu receptors) are predominantly expressed presynaptically throughout the central nervous system (CNS) where they regulate the release of glutamate and GABA. These receptors have recently been shown to be anchored by transsynaptic expression of the laminin proteins ELFN1 and ELFN2. In particular, the mGlu
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Profiling the Impact of mGlu · full record | OpenQuestion